WA
EBS icon

Whitebox Advisors’s Emergent Biosolutions EBS Stock Holding History

Whitebox Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40,427
Closed -$338K – 281
2024
Q3 		$338K Buy
+40,427
New +$368K 0.01% 170

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Whitebox Advisors's EBS Position: Q4 2024 in Review

Whitebox Advisors sold out of Emergent Biosolutions (EBS) in Q4 2024, closing a stake of 40,427 shares — an estimated $338K sold.

Whitebox Advisors first reported a position in EBS in Q3 2024 and held it in 1 quarter. The position peaked at $338K in Q3 2024. 156 funds tracked by Wall St. Rank hold EBS as of Q4 2024.

  • Whitebox Advisors reported no remaining Emergent Biosolutions position as of Q4 2024 after selling out during the quarter.
  • Whitebox Advisors sold 40,427 Emergent Biosolutions shares in Q4 2024, an estimated $338K.
  • Whitebox Advisors first reported a position in Emergent Biosolutions in Q3 2024 and held it in 1 quarter.
  • Whitebox Advisors's Emergent Biosolutions position peaked at $338K in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2024.

Based on Whitebox Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.